Last edition
News about "refractory multiple myeloma"
Pfizer Launches Elranatamab in India for Relapsed or Refractory Multiple Myeloma
Pfizer has launched Elranatamab in India for adults with Relapsed or Refractory Multiple Myeloma (RRMM) who have received at least four prior therapies. The BCMA-directed bispecific antibody is available as a fixed-dose subcutaneous injection, offering a novel treatment option for heavily pretreated multiple myeloma patients.
Refractory Multiple Myeloma | 03/06/2026 | By News Bureau
J&J's Tecvayli Cuts Death Risk in Phase III Multiple Myeloma Study
Phase III MajesTEC-9 shows Tecvayli significantly improves survival, reducing progression or death risk by 71 percent versus standard care in relapsed multiple myeloma.
Refractory Multiple Myeloma | 15/01/2026 | By News Bureau | 136
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy